Video

Dr. Siegel on the Importance of Bisphosphonates

Author(s):

David S. Siegel, MD, PhD

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates for managing bone health in patients with multiple myeloma.

Related Videos
Fred Saad, CQ, MD, FRCS, FCAHS
Ajai Chari, MD
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Related Content
FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Neha Korde, MD, of Memorial Sloan Kettering Cancer Center
October 2nd 2024

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens School of Medicine
October 2nd 2024

BPd Maintains QOL vs PVd, Supporting Its Use as a New SOC in R/R Myeloma

Surbhi Sidana, MD
October 1st 2024

Cilta-Cel Shows Real-World Feasibility and Efficacy With Acceptable Safety in R/R Myeloma